Vicore Pharma Holding AB (STU:6Y4) YoY EBITDA Growth : -232.00% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Vicore Pharma Holding AB's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -232.00%.

Vicore Pharma Holding AB's EBITDA per Share for the three months ended in Mar. 2025 was €-0.03.

Vicore Pharma Holding AB YoY EBITDA Growth Historical Data

The historical data trend for Vicore Pharma Holding AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB YoY EBITDA Growth Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

-27.78

-57.71

12.28

18.57

62.81

Vicore Pharma Holding AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															135.71	38.03	8.16	62.22	-232.00

Vicore Pharma Holding AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Vicore Pharma Holding AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-0.106	-	-0.285)	/	\| -0.285 \|
=	62.81 %

Vicore Pharma Holding AB's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-0.033	-	0.025)	/	\| 0.025 \|
=	-232.00 %

Vicore Pharma Holding AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

VICO:Sweden 6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines